PMID- 38025813
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231201
IS  - 2218-6751 (Print)
IS  - 2226-4477 (Electronic)
IS  - 2218-6751 (Linking)
VI  - 12
IP  - 10
DP  - 2023 Oct 31
TI  - Safety and efficacy of thoracic radiotherapy combined with chemo-immunotherapy in 
      patients with extensive-stage small cell lung cancer: a multicenter retrospective 
      analysis.
PG  - 1987-2000
LID - 10.21037/tlcr-23-294 [doi]
AB  - BACKGROUND: Immunotherapy has greatly increased the survival time of patients 
      with extensive-stage small cell lung cancer (ES-SCLC), and is now a standard 
      first-line treatment for these patients. Increasing evidence suggests a possible 
      synergistic effect between immunotherapy and radiotherapy, yet there is a paucity 
      of evidence regarding the efficacy and safety of thoracic radiotherapy (TRT) 
      combined with chemo-immunotherapy for ES-SCLC. METHODS: The medical records of 78 
      consecutive patients with ES-SCLC who received TRT in combination with 
      chemo-immunotherapy at Jinling Hospital and Jiangsu Cancer Hospital from January 
      2019 to January 2023 were retrospectively reviewed. The median overall survival 
      (mOS) time and median progression-free survival (mPFS) time were used to evaluate 
      efficacy, and the incidence of adverse events (AEs) was used to evaluate safety. 
      RESULTS: The median follow-up time was 31.9 months, the objective response rate 
      (ORR) was 59%, and the disease control rate (DCR) was 89.8%. The mOS time was 
      20.0 months, and the 6-month OS rate was 95%. The mPFS time was 9.2 months, and 
      the 6-month PFS rate was 78%. There were no treatment-related deaths. The 
      incidence of pneumonitis was 23.1%, the incidence of radiation esophagitis was 
      5.1%, and 2 patients experienced high-grade pneumonitis. Primary liver metastasis 
      was a predictor of poor OS and PFS. Patients who received consolidative TRT after 
      chemo-immunotherapy experienced more benefit than those who received TRT as 
      palliative or salvage treatment for superior vena cava syndrome or disease 
      progression. CONCLUSIONS: TRT is a feasible treatment for patients who receive 
      chemo-immunotherapy for the management of ES-SCLC in consideration of its 
      considerable efficacy and tolerable safety risk. This treatment is especially 
      useful for patients without primary liver metastasis and who receive 
      consolidative TRT after chemo-immunotherapy. Large-scale prospective studies are 
      needed to confirm the efficacy and safety of this treatment modality.
CI  - 2023 Translational Lung Cancer Research. All rights reserved.
FAU - Cai, Zijing
AU  - Cai Z
AD  - Department of Respiratory and Critical Care Medicine, Affiliated Jinling 
      Hospital, Nanjing Medical University, Nanjing, China.
FAU - Gu, Xiaoling
AU  - Gu X
AD  - Department of Respiratory and Critical Care Medicine, Affiliated Jinling 
      Hospital, Medical School of Nanjing University, Nanjing, China.
FAU - Xie, Jingyuan
AU  - Xie J
AD  - Department of Respiratory and Critical Care Medicine, Affiliated Jinling 
      Hospital, Medical School of Nanjing University, Nanjing, China.
FAU - Cheng, Di
AU  - Cheng D
AD  - Department of Respiratory and Critical Care Medicine, Affiliated Jinling 
      Hospital, Medical School of Nanjing University, Nanjing, China.
FAU - Chen, Jiayan
AU  - Chen J
AD  - Department of Respiratory and Critical Care Medicine, Affiliated Jinling 
      Hospital, Nanjing Medical University, Nanjing, China.
FAU - Cheng, Jing
AU  - Cheng J
AD  - Department of Respiratory and Critical Care Medicine, Affiliated Jinling 
      Hospital, Medical School of Nanjing University, Nanjing, China.
FAU - Ye, Jinjun
AU  - Ye J
AD  - Department of Radiotherapy, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer 
      Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, China.
FAU - Lv, Tangfeng
AU  - Lv T
AD  - Department of Respiratory and Critical Care Medicine, Affiliated Jinling 
      Hospital, Nanjing Medical University, Nanjing, China.
AD  - Department of Respiratory and Critical Care Medicine, Affiliated Jinling 
      Hospital, Medical School of Nanjing University, Nanjing, China.
LA  - eng
PT  - Journal Article
DEP - 20231019
PL  - China
TA  - Transl Lung Cancer Res
JT  - Translational lung cancer research
JID - 101646875
PMC - PMC10654438
OTO - NOTNLM
OT  - Extensive-stage small cell lung cancer (ES-SCLC)
OT  - chemo-immunotherapy
OT  - chemotherapy
OT  - immunotherapy
OT  - thoracic radiotherapy (TRT)
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at 
      https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-294/coif). TL serves as 
      an unpaid editorial board member of Translational Lung Cancer Research from 
      December 2022 to November 2023. The other authors have no conflicts of interest 
      to declare.
EDAT- 2023/11/29 18:42
MHDA- 2023/11/29 18:43
PMCR- 2023/10/31
CRDT- 2023/11/29 16:37
PHST- 2023/05/04 00:00 [received]
PHST- 2023/09/14 00:00 [accepted]
PHST- 2023/11/29 18:43 [medline]
PHST- 2023/11/29 18:42 [pubmed]
PHST- 2023/11/29 16:37 [entrez]
PHST- 2023/10/31 00:00 [pmc-release]
AID - tlcr-12-10-1987 [pii]
AID - 10.21037/tlcr-23-294 [doi]
PST - ppublish
SO  - Transl Lung Cancer Res. 2023 Oct 31;12(10):1987-2000. doi: 10.21037/tlcr-23-294. 
      Epub 2023 Oct 19.